Luminary Therapeutics a clinical stage gamma delta allogeneic cellular therapy company.MINNEAPOLIS, MN, USA, July 19, 2022 /EINPresswire.com/ — Luminary Therapeutics was selected as a 2022/2023 Showcase Company in NIH/NCI’s investor initiative program. Luminary Therapeutics is a clinical stage allogeneic cellular therapy company. Its gamma delta expansion platform coupled with its non-viral cell engineering process is unique in the industry.
Luminary Therapeutics’ novel ligand-based CAR designed to bind three targets is set to enter the clinic in the early Fall of 2022 to treat Mantle Cell Cancer and Multipe Myeloma with its LMY-920 Cell Therapy. This BAFF CAR-T product was developed by Reshmi Parameswaran, PhD, an assistant professor at the Case Western Reserve School of Medicine and a faculty member in the Division of Hematology and Oncology, Department of Medicine, and the Seidman Cancer Center at University Hospitals (UH) in Cleveland.
“This recognition by the NIH is a validation on the thoughtful work completed to bring this cell therapy into the clinic. Luminary achieved this clinical milestone in a short two year period attributable to our ability to manufacture a cell therapy with a significantly lower cost and reduced time to clinic via a non-viral gene modification manufacturing method,” said Jeff Liter Luminary’s CEO.
About Luminary Therapeutics, Inc.
Luminary is a clinical stage allogeneic cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Luminary was founded by the team from B-MoGen that achieved a successful 5X exit in only three years. We are seeking Series A financing with venture firms or strategic partners to support our 1st clinical trial and development of our disruptive Universal Receptor that can modulate antigen specificity.
For more information visit www.luminarytx.com
Media and Investor Relations
Contact: Jeff Liter